![Applied StemCell Inc on X: "ASC can develop preclinical assays to determine efficacy, pharmacodynamic, dose-ranging studies, biodistribution, and develop other IND-enabling assays to measure potency and toxicity of the drug including NHPs, Applied StemCell Inc on X: "ASC can develop preclinical assays to determine efficacy, pharmacodynamic, dose-ranging studies, biodistribution, and develop other IND-enabling assays to measure potency and toxicity of the drug including NHPs,](https://pbs.twimg.com/media/E8C2rZoUcAEdt4d.jpg)
Applied StemCell Inc on X: "ASC can develop preclinical assays to determine efficacy, pharmacodynamic, dose-ranging studies, biodistribution, and develop other IND-enabling assays to measure potency and toxicity of the drug including NHPs,
![Verve Therapeutics on X: "Today we are excited to announce anticipated 2022 milestones including timing of first HeFH patient treated with VERVE-101 & initiation of IND-enabling studies for our ANGPTL3 program. Read Verve Therapeutics on X: "Today we are excited to announce anticipated 2022 milestones including timing of first HeFH patient treated with VERVE-101 & initiation of IND-enabling studies for our ANGPTL3 program. Read](https://pbs.twimg.com/media/FIvaH41WYAIeLyt.png:large)
Verve Therapeutics on X: "Today we are excited to announce anticipated 2022 milestones including timing of first HeFH patient treated with VERVE-101 & initiation of IND-enabling studies for our ANGPTL3 program. Read
![The alignment of major PK/PD related studies with the decision points... | Download Scientific Diagram The alignment of major PK/PD related studies with the decision points... | Download Scientific Diagram](https://www.researchgate.net/publication/325623009/figure/fig3/AS:634865636610048@1528375171691/The-alignment-of-major-PK-PD-related-studies-with-the-decision-points-of-mAb-development.png)